The Superbug That Escaped the Hospital Is Now in Your Community

A bacterium long considered a hospital problem has been quietly establishing itself in communities across the United States. Researchers from Hackensack Meridian's Center for Discovery and Innovation and Quest Diagnostics screened more than 2,000 outpatient samples and found 267 strains of multidrug-resistant Klebsiella pneumoniae spreading not just within hospitals but across state lines, driven by a single mobile genetic element. The findings, published in Nature Communications, suggest the threat is wider and more entrenched than public health surveillance has recognized.

Multidrug-Resistant Klebsiella pneumoniae Is Spreading Beyond Hospital Walls

Klebsiella pneumoniae has a well-established reputation in medicine: it is the leading cause of hospital-acquired pneumonia and the second-leading cause of urinary tract infections worldwide. It has been linked to at least 800,000 deaths globally. For decades, the assumption was that highly resistant strains thrived mainly in healthcare environments, where vulnerable patients and heavy antibiotic use created conditions for resistance to take hold.

This study suggests that assumption is increasingly wrong. Of the 267 multidrug-resistant strains identified, nearly half formed transmission clusters that crossed multiple states. That pattern points to active community dissemination, not sporadic spillover from hospitals. A CDC analysis cited by the researchers had already flagged a 53.3% increase in bacteria carrying Extended-Spectrum Beta-Lactamase (ESBL) genes between 2012 and 2017, hinting at community transmission. The new genomic survey confirms the trend at a national scale, revealing regional, statewide, and multistate spread that had gone largely undetected. This mirrors a broader pattern: research tracking global rise in community-acquired MDR infections has documented a 43% worldwide increase in multidrug-resistant infections, with community-acquired cases rising sharply in regions with high antibiotic misuse.

Elderly Women With UTIs Face Shrinking Treatment Options

The most affected group identified in the study is elderly women with urinary tract infections. UTIs are already the most common outpatient infection in older women, and oral antibiotics are the standard first-line treatment. The problem is that the strains now circulating in communities carry resistance to precisely those antibiotics. As multidrug resistance in community infections climbs, the practical consequence is straightforward: a woman who develops a UTI at home, sees her primary care doctor, and receives a standard antibiotic prescription may not get better.

When oral options fail, patients often end up in hospitals for intravenous treatment, transforming what should be a routine outpatient infection into a costly and potentially dangerous admission. The economic burden of resistant infections in the United States is already estimated at between $4.1 billion and $5.1 billion annually in direct costs. Widespread community transmission of K. pneumoniae could push those numbers higher while disproportionately burdening elderly patients who are least equipped to handle hospitalization.

"For a long time, highly resistant superbugs were primarily considered a problem for hospitals, but this study reveals a dangerous shift. These bacteria are spreading and causing common infections that are resistant to the recommended antibiotics used to treat them."

• Meghan W. Starolis, MS, Ph.D.

Genomic Sequencing Traced a Plasmid Driving Nationwide Resistance

The study's methodological backbone was a nationwide genomic survey of 2,006 ceftriaxone-nonsusceptible outpatient isolates collected from patients across 42 U.S. states. Researchers performed capsule and O-antigen profiling alongside full genome analysis to map how strains were related and how resistance was moving between bacterial populations.

The culprit that kept appearing was the blaCTX-M-15 gene, an ESBL variant carried on IncFIB(Kpn3) plasmids. Plasmids are small, circular pieces of DNA that bacteria can pass to one another independently of normal reproduction, which is why resistance can spread so rapidly through a bacterial population. The CTX-M-15 gene is notable for doing double duty: it encodes resistance to beta-lactam antibiotics while also helping bacteria tolerate stress and metal exposure. That dual function likely helps resistant strains survive in environments well outside clinical settings. Whole-genome sequencing for pathogen tracking has proven superior to older typing methods for reconstructing these transmission chains, and the approach here produced a granular picture of how a single plasmid lineage can drive multistate spread.

Surveillance Gaps Leave the Full Scope of Spread Unknown

The researchers are candid about what the study cannot answer. Barry Kreiswirth, Ph.D., one of the study's lead scientists, described the findings as establishing a baseline: "We need to keep looking at this to better understand the extent of the problem. But this is definite confirmation that there is a problem, and it needs to be addressed."

Community surveillance for K. pneumoniae is far less systematic than hospital-based monitoring. Outpatient labs do not uniformly perform resistance profiling, and patients who respond to alternative antibiotics may never generate a sample that enters a surveillance database. The 2,006 isolates in this study represent only ceftriaxone-nonsusceptible cases from patients who sought care, almost certainly an undercount of the full burden. The researchers call for continued genomic surveillance to detect the emergence of future high-risk clones before they become entrenched.

A Genetic Blueprint for Vaccines and New Treatments

One concrete contribution of the study is its value for therapeutic development. The capsule and O-antigen profiling revealed a manageable subset of serotypes that could provide wide coverage for a K. pneumoniae vaccine. No licensed vaccine against this pathogen currently exists, and treatment options are narrowing as resistance spreads. The genetic map produced by this research gives developers a target.

Kreiswirth's team framed the findings as both a warning and a roadmap: "Our work shows that there is a rapidly evolving, plasmid-driven epidemic of community-associated multidrug resistant Klebsiella pneumoniae across the United States." Addressing it will require coordinated action across surveillance, antibiotic stewardship, and vaccine development. The CDC's framework for controlling antimicrobial resistance emphasizes exactly this combination: preventing infections, optimizing treatment, and halting the spread of resistance once it appears. Whether public health infrastructure moves quickly enough to match the pace of the pathogen remains the open question.

Evidence rating

EMERGING — 78/100

Caveats:

• This is a surveillance and genomic screening study — it establishes spread and strain diversity but does not establish causation or treatment outcomes.
• Quest Diagnostics, a commercial clinical laboratory, contributed data and personnel to this research; findings should be interpreted with that context in mind.
• The study has not yet been independently replicated at comparable scale in other national populations.
• No intervention or probiotic/microbiome-modulating strategy is tested here; the findings are descriptive and epidemiological.

Large cross-sectional genomic surveillance study screening over 2,000 clinical isolates from 42 US states. Identifies patterns of multidrug-resistant strain dissemination and named resistance mechanisms but establishes association and spread rather than causation. Consistent with prior CDC surveillance data showing rising ESBL prevalence, though not yet independently replicated at this geographic scale.

References

1. Jianping Jiang, Austin J. Terlecky, Kevin J. Rome, et al. (2026). Nationwide spread of multidrug resistant Klebsiella pneumoniae across US communities. Nature Communications. https://doi.org/10.1038/s41467-026-74379-0
2. Andrea Marino, Antonino Maniaci, Mario Lentini, et al. (2025). The Global Burden of Multidrug-Resistant Bacteria. Epidemiologia. https://doi.org/10.3390/epidemiologia6020021
3. Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections. mdpi.com. https://www.mdpi.com/2079-6382/13/11/1070
4. The Health and Economic Burden of Resistance – Combating Antimicrobial Resistance and Protecting the Miracle of Modern Medicine – NCBI. NIH. https://www.ncbi.nlm.nih.gov/books/NBK589650/
5. Gulam Mustafa Hasan, Taj Mohammad, Anas Shamsi, Sukhwinder Singh Sohal, Md. Imtaiyaz Hassan (2025). Applications of Genome Sequencing in Infectious Diseases: From Pathogen Identification to Precision Medicine. Pharmaceuticals. https://doi.org/10.3390/ph18111687
6. Controlling the Emergence and Spread of Antimicrobial Resistance – CDC. cdc.gov. https://www.cdc.gov/drugresistance/about/controlling-emergence-spread.html